Adult: For treatment of refractory cases or when topical treatment is inappropriate: 0.5-1 g as single or in divided doses. Duration of treatment: 2-4 weeks (tinea corporis); 4-8 weeks (tinea capitis, pedis); 8-12 weeks (refractory cases of tinea capitis); 4-6 months (tinea unguium). Child: >2 years As tab or oral suspension: 10 mg/kg daily in divided doses.
Topical/Cutaneous Tinea pedis
Adult: As 1% spray: 1 spray (0.4 mg) once daily, may be increased to 3 sprays (1.2 mg) once daily, if necessary, depending on the severity of the condition. Continue treatment for 10 days after all lesions have disappeared. Max duration of treatment: 4 weeks.
Should be taken with food. Take immediately after meals.
Hypersensitivity to griseofulvin and penicillin. Systemic lupus erythematosus (SLE), porphyria. Severe hepatic impairment. Pregnancy.
Mild to moderate hepatic impairment. Children. Lactation. Men should not father a child during and for 6 months after treatment.
Significant: Onset or exacerbation of SLE, photosensitivity reaction, rarely, leucopenia, granulocytopenia. Gastrointestinal disorders: Diarrhoea, dry mouth, vomiting, nausea, gastric discomfort, epigastric distress, oral candidiasis. Rarely, gastrointestinal haemorrhage. General disorders and administration site conditions: Fatigue. Nervous system disorders: Headache, dizziness, paraesthesia, impaired coordination, peripheral neuropathy. Psychiatric disorders: Confusion, insomnia. Renal and urinary disorders: Rarely, nephrosis, proteinuria. Skin and subcutaneous tissue disorders: Rash, urticaria, irritation (e.g. stinging, burning). Potentially Fatal: Severe skin reactions (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme), photosensitivity, hepatotoxicity (e.g. jaundice, elevated LFT or bilirubin).
This drug may cause drowsiness, confusion, dizziness and impaired coordination, if affected, do not drive or operate machinery. Avoid exposure to sunlight or UV sources. Spray: Avoid exposure to open flame or other source of ignition during or after application.
Monitor CBC (long-term treatment), liver and renal function. Assess for signs of severe skin reaction.
Decreased serum concentrations of coumarin anticoagulants, oral contraceptives, ciclosporin and salicylates. Decreased serum concentrations of griseofulvin with phenylbutazone, barbiturates (e.g. phenobarbital) and other sedative and hypnotic drugs.
Increased absorption and plasma concentration with food, particularly high-fat meals. Enhanced effects (e.g. nausea, vomiting, flushing, tachycardia, severe hypotension) of alcohol.
Description: Griseofulvin inhibits fungal cell division at metaphase by disrupting the mitotic spindle structure of the cell. It binds to human keratin and make it resistant to fungal infections; may also interfere with deoxyribonucleic acid (DNA) production. Pharmacokinetics: Absorption: Almost completely absorbed primarily from the duodenum and to a lesser extent from jejunum and ileum. Food enhances absorption, particularly high-fat meal. Time to peak plasma concentration: Approx 4 hours (microsize griseofulvin). Distribution: Distributed in the keratin layer of the skin, hair, and nails, and concentrates in the liver, fat and skeletal muscles. Crosses the placenta. Volume of distribution: Approx 1.5 L. Metabolism: Extensively metabolised in the liver to 6-desmethylgriseofulvin and glucuronide conjugate. Excretion: Via urine (<1% as unchanged drug); faeces (approx 33%); perspiration. Elimination half-life: 9-24 hours.
Store between 20-25°C. Protect from light. Spray: Protect from direct light and heat.